NovoCure Ltd Shares Approach 52-Week High - Market Mover
The shares closed 1.9% below its 52-week high of $220.48, with trading volume lower than its 30 day average
Jun 11, 2021 by Kwhen Finance Editors
NovoCure Ltd (NVCR) shares closed today at 1.9% below its 52 week high of $220.48, giving the company a market cap of $22B. The stock is currently up 25.7% year-to-date, up 220.3% over the past 12 months, and up 1521.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 1.2%.
Trading Activity
- Trading volume this week was 13.8% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 1.1.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
- The stock closed at 1.5% higher than its 5-day moving average, 10.2% higher than its 20-day moving average, and 25.5% higher than its 90-day moving average.
Fundamentals & Catalysts
- Over the past 12 months the company generated $43 million in earnings before interest and taxes from $527 million in revenue. It currently holds $864 million in cash and $110 million in debt.
- Its forward price-to-earnings (P/E) ratio of 7649.99928041368 is higher than its current P/E ratio of 1917.66, implying that analysts are expecting a decrease in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 76.08. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 2.87 which means it currently has $2.87 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 56.69. This means that the stock is trading at a premium of 57 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 40.01.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 39.44.
P/E
1917.66
EBITDA
$43M
P/Book
56.69
Mkt Cap
$22B
P/Sales
40.01
Revenue
$527M
EPS (TTM)
0.11
PEG Ratio
76.08
EV/Revenue
39.44
Total Cash
$864M
Debt/Equity
2.87
Forward P/E
7650.00
Current Debt
$110M
Gross Profit
$418M
Dividend Date
-
Earnings Date
2021-07-29
Profit Margin
0.02
Revenue/Share
5.10
Total Revenue
$527M
Enterprise Val
$20B
Put/Call Ratio
0.88
Revenue/Employee
0.00
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| NovoCure Ltd | -0.6 | 25.7 | 220.3 | -1.4 | 292.6 |
| Dow Jones Industrial Average | 0.0 | 13.6 | 30.1 | -1.3 | 41.6 |
| S&P 500 Index | 0.2 | 13.7 | 34.9 | -0.1 | 45.2 |
| Health Care | -0.8 | 10.7 | 24.5 | -0.3 | 33.3 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by 3.0%
- The company's stock price performance over the past 12 months lags the peer average by -53.1%
- The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 305.2% higher than the average peer.
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| NovoCure Ltd | NVCR | 1917.7 | 25.7 | 220.3 | -1.4 | 292.6 |
| Peer Avg | N/A | 473.2 | 24.9 | 470.0 | -36.6 | 608.9 |
| NovoCure Ltd | NVCR | 1917.7 | 25.7 | 220.3 | -1.4 | 292.6 |
| Novavax, Inc. | NVAX | -24.7 | 83.8 | 355.8 | -38.4 | 368.9 |
| Orchard Therapeutics plc - ADR | ORTX | 0 | 19.9 | -35.4 | -43.0 | 37.8 |
| Organovo Holdings Inc | ONVO | 0 | -29.7 | 1339.3 | -63.9 | 1736.2 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: